Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Williams Companies Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while Williams Companies Inc trades at $74.41 (market cap $92.92B). The key difference: Williams Companies Inc is far larger — about 11.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Williams Companies Inc pays a 2.76% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | WMB | |
|---|---|---|
Market Cap | $8.04B | $92.92B |
Sector | Health | Energy |
52-Week High | $339.75 | $79.40 |
52-Week Low | $241.71 | $56.51 |
Enterprise Value | $7.85B | $122.31B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Williams Companies (WMB) trades at $74.46, down 0.75% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported revenue of $11.95 billion in 2025 with a net income margin of 23.4%, and recent news highlights a $5.34 billion Blackstone-led investment to accelerate power projects. Valuation ratios include a P/E of 32.66 and P/B of 7.03, reflecting premium pricing relative to historical levels.
WMB presents a positive outlook with a consensus price target of $85.67, indicating 15% upside potential, supported by stable cash flows and strategic investments in energy infrastructure. Risks include exposure to natural gas price volatility and high debt levels, but the company's fee-based contracts and growth initiatives provide a buffer against market swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
